Cross Country Healthcare, Inc. (the Company) (Nasdaq: CCRN)
today announced financial results for its first quarter ended March
31, 2025.
SELECTED FINANCIAL INFORMATION:
Variance
Variance
Q1 2025 vs
Q1 2025 vs
Dollars are in thousands, except per share
amounts
Q1 2025
Q1 2024
Q4 2024
Revenue
$
293,408
(23
)
%
(5
)
%
Gross profit margin*
20.0
%
(40
)
bps
—
bps
Net loss attributable to common
stockholders
$
(490
)
(118
)
%
87
%
Diluted EPS
$
(0.02
)
$
(0.10
)
$
0.10
Adjusted EBITDA*
$
8,619
(44
)
%
(7
)
%
Adjusted EBITDA margin*
2.9
%
(110
)
bps
(10
)
bps
Adjusted EPS*
$
0.06
$
(0.13
)
$
0.02
Cash flows provided by operations
$
5,681
(5
)
%
(77
)
%
* Represents amounts that are not
calculated in accordance with U.S. generally accepted accounting
principles (GAAP) and are referred to as non-GAAP measures. Please
refer to the accompanying discussion below of how these non-GAAP
financial measures are calculated and used under “Non-GAAP
Financial Measures” and the tables reconciling these measures to
the closest GAAP measure.
First Quarter Business Highlights
- Homecare Staffing experienced double-digit sequential and
year-over-year revenue growth
- Physician Staffing experienced year-over-year revenue
growth
- Cross Country Education experienced double-digit sequential
revenue growth
- Continued strong balance sheet with $81 million of cash on hand
and no debt as of March 31, 2025
“Our first quarter results reflect solid execution with both
Homecare and Physician Staffing business reporting solid year over
year growth,” said John A. Martins, President and Chief Executive
Officer of Cross Country Healthcare. He continued, “As the market
for core nurse and allied continues to stabilize, we remain focused
on driving productivity across our business, leveraging our
investments in AI automation as well as our cost-effective center
of excellence in India to fuel efficiency and improved
profitability. Looking ahead, we continue working with Aya
Healthcare and the Federal Trade Commission towards the successful
consummation of the merger transaction in the second half of this
year.”
Regarding the Company’s pending acquisition by Aya Healthcare,
Martins further commented, ”We recently learned of the passing of
Alan Braynin, founder, former CEO & President of Aya
Healthcare, and our hearts go out to his family, friends and to the
thousands of Aya employees. Alan was a pioneer and transformational
force in the healthcare staffing industry whose presence will be
missed by many.”
First quarter consolidated revenue was $293.4 million, a
decrease of 23% year-over-year and 5% sequentially. Consolidated
gross profit margin was 20.0%, down 40 basis points year-over-year
and flat sequentially. Net loss attributable to common stockholders
was $0.5 million, as compared to net income of $2.7 million in the
prior year and a net loss of $3.8 million in the prior quarter.
Diluted earnings per share (EPS) was a net loss of $0.02, as
compared to net income of $0.08 in the prior year and a net loss of
$0.12 in the prior quarter. Adjusted earnings before interest,
taxes, depreciation, and amortization (EBITDA) was $8.6 million, or
2.9% of revenue, as compared with $15.3 million, or 4.0% of
revenue, in the prior year, and $9.3 million, or 3.0% of revenue,
in the prior quarter. Adjusted EPS was $0.06, as compared to $0.19
in the prior year and $0.04 in the prior quarter.
Quarterly Business Segment Highlights
Nurse and Allied Staffing
Revenue was $242.3 million, a decrease of 27% year-over-year and
6% sequentially. Contribution income was $17.2 million, as compared
to $27.2 million in the prior year and $20.3 million in the prior
quarter. Average field contract personnel on a full-time equivalent
(FTE) basis was 7,411, as compared with 9,124 in the prior year and
7,621 in the prior quarter. Revenue per FTE per day was $360, as
compared to $397 in the prior year and $363 in the prior
quarter.
Physician Staffing
Revenue was $51.1 million, an increase of 9% year-over-year and
a decrease of 4% sequentially. Contribution income was $4.0
million, as compared to $3.1 million in the prior year and $3.5
million in the prior quarter. Total days filled were 22,692, as
compared with 23,785 in the prior year and 25,427 in the prior
quarter. Revenue per day filled was $2,253, as compared with $1,976
in the prior year and $2,085 in the prior quarter.
Cash Flow and Balance Sheet Highlights
Net cash provided by operating activities for the three months
ended March 31, 2025 was $5.7 million, as compared to $6.0 million
for the three months ended March 31, 2024 and $24.2 million for the
three months ended December 31, 2024. We experienced a 15-day
year-over-year improvement in days’ sales outstanding.
During the first quarter of 2025, the Company did not repurchase
any shares of its common stock. As of March 31, 2025, the Company
had 32.5 million unrestricted shares outstanding and $40.5 million
remaining for share repurchase.
As of March 31, 2025, the Company had $80.7 million in cash and
cash equivalents with no debt outstanding. There were no borrowings
drawn under its revolving senior secured asset-based credit
facility (ABL). As of March 31, 2025, borrowing base availability
under the ABL was $148.4 million, with $133.5 million of
availability net of $14.9 million of letters of credit.
CONFERENCE CALL
As previously disclosed, on December 3, 2024, the Company
entered into a merger agreement with Aya Healthcare, Inc. and
certain of its subsidiaries (Aya Merger, and such agreement, the
Merger Agreement). In light of the pending transaction, the Company
will not host an earnings conference call to review first quarter
2025 financial results, nor will it provide forward-looking
guidance. This press release is also posted on the Company’s
website at ir.crosscountry.com.
ABOUT CROSS COUNTRY HEALTHCARE
Cross Country Healthcare, Inc. is a market-leading, tech-enabled
workforce solutions and advisory firm with 39 years of industry
experience and insight. We help clients tackle complex
labor-related challenges and achieve high-quality outcomes, while
reducing complexity and improving visibility through data-driven
insights.
Copies of this and other press releases, information about the
Company, as well as information about the Aya Merger, can be
accessed online at ir.crosscountry.com. Stockholders and
prospective investors can also register to automatically receive
the Company’s press releases, filings with the Securities and
Exchange Commission (SEC), and other notices by e-mail.
NON-GAAP FINANCIAL MEASURES
This press release and the accompanying financial statement
tables reference non-GAAP financial measures, such as gross profit
margin, adjusted EBITDA, adjusted EBITDA margin, and adjusted EPS.
Such non-GAAP financial measures are provided as additional
information and should not be considered substitutes for, or
superior to, financial measures calculated in accordance with GAAP.
Such non-GAAP financial measures are provided for consistency and
comparability to prior year results; furthermore, management
believes such non-GAAP financial measures are useful to investors
when evaluating the Company’s performance, as such non-GAAP
financial measures exclude certain items that management believes
are not indicative of the Company’s future operating performance.
Pro forma measures, if applicable, are adjusted to include the
results of our acquisitions, and exclude the results of
divestments, as if the transactions occurred in the beginning of
the periods mentioned. Such non-GAAP financial measures may differ
materially from the non-GAAP financial measures used by other
companies. The financial statement tables that accompany this press
release include a reconciliation of each non-GAAP financial measure
to the most directly comparable GAAP financial measure and a more
detailed discussion of each financial measure; as such, the
financial statement tables should be read in conjunction with the
presentation of these non-GAAP financial measures.
FORWARD-LOOKING STATEMENTS
This press release contains “forward-looking statements” within
the Private Securities Litigation Reform Act of 1995. Any
statements contained in this press release that are not statements
of historical fact, including statements relating to our future
results (including business trends); statements regarding the
proposed Aya Merger; the expected timing and closing of the
proposed Aya Merger; the Company’s ability to consummate the
proposed Aya Merger; the expected benefits of the proposed Aya
Merger and other considerations taken into account by the Board in
approving the proposed Aya Merger; the amounts to be received by
stockholders in connection with the proposed Aya Merger; and
expectations for the Company prior to and following the closing of
the proposed Aya Merger, may be deemed to be forward-looking
statements. All such forward-looking statements are intended to
provide management’s current expectations for the future of the
Company based on current expectations and assumptions relating to
the Company’s business, the economy and other future conditions.
Forward-looking statements generally can be identified through the
use of words such as “believes,” “anticipates,” “may,” “should,”
“will,” “plans,” “projects,” “expects,” “expectations,”
“estimates,” “forecasts,” “predicts,” “targets,” “prospects,”
“strategy,” “signs,” and other words of similar meaning in
connection with the discussion of future performance, plans,
actions or events. Because forward-looking statements relate to the
future, they are subject to inherent risks, uncertainties and
changes in circumstances that are difficult to predict. Such risks
and uncertainties include, among others: (i) the timing to
consummate the proposed Aya Merger, (ii) the risk that a condition
of closing of the proposed Aya Merger may not be satisfied or that
the closing of the proposed Aya Merger might otherwise not occur,
(iii) the risk that a regulatory approval that may be required for
the proposed Aya Merger is not obtained or is obtained subject to
conditions that are not anticipated, (iv) the diversion of
management time on transaction-related issues, (v) risks related to
disruption of management time from ongoing business operations due
to the proposed Aya Merger, (vi) the risk that any announcements
relating to the proposed Aya Merger could have adverse effects on
the market price of the common stock of the Company, (vii) the risk
that the proposed Aya Merger and its announcement could have an
adverse effect on the ability of the Company to retain customers
and retain and hire key personnel and maintain relationships with
its suppliers and customers, (viii) the occurrence of any event,
change or other circumstance or condition that could give rise to
the termination of the Merger Agreement, including in circumstances
requiring the Company to pay a termination fee, (ix) the risk that
competing offers will be made, (x) unexpected costs, charges or
expenses resulting from the Aya Merger, (xi) potential litigation
relating to the Aya Merger that could be instituted against the
parties to the Merger Agreement or their respective directors,
managers or officers, including the effects of any outcomes related
thereto, (xii) worldwide economic or political changes that affect
the markets that the Company’s businesses serve which could have an
effect on demand for the Company’s services and impact the
Company’s profitability, (xiii) effects from global pandemics,
epidemics or other public health crises, (xiv) changes in
marketplace conditions, such as alternative modes of healthcare
delivery, reimbursement and customer needs, and (xv) disruptions in
the global credit and financial markets, including diminished
liquidity and credit availability, changes in international trade
agreements, including tariffs and trade restrictions,
cyber-security vulnerabilities, foreign currency volatility, swings
in consumer confidence and spending, costs of providing services,
retention of key employees, and outcomes of legal proceedings,
claims and investigations. Accordingly, actual results may differ
materially from those contemplated by these forward-looking
statements. Investors, therefore, are cautioned against relying on
any of these forward-looking statements. They are neither
statements of historical fact nor guarantees or assurances of
future performance. Additional information regarding the factors
that may cause actual results to differ materially from these
forward-looking statements is available in the Company’s filings
with the SEC, including the risks and uncertainties identified in
Part I, Item 1A - Risk Factors of the Company’s Annual Report on
Form 10-K for the year ended December 31, 2024, as amended by
Amendment No. 1 on Form 10-K/A, and in the Company’s other filings
with the SEC. The list of factors is not intended to be
exhaustive.
These forward-looking statements speak only as of the date of
this press release, and the Company does not assume any obligation
to update or revise any forward-looking statement made in this
press release or that may from time to time be made by or on behalf
of the Company.
Cross Country Healthcare,
Inc.
Consolidated Statements of
Operations
(Unaudited, amounts in
thousands, except per share data)
Three Months Ended
March 31,
March 31,
December 31,
2025
2024
2024
Revenue from services
$
293,408
$
379,174
$
309,940
Operating expenses:
Direct operating expenses
234,750
301,877
247,948
Selling, general and administrative
expenses
52,486
63,252
55,573
Credit loss expense (income)
35
1,290
(228
)
Depreciation and amortization
4,772
4,642
4,341
Acquisition and integration-related
costs
2,041
—
4,216
Restructuring costs
301
938
281
Legal and other losses (gains)
—
3,650
(928
)
Impairment charges
—
604
2,170
Total operating expenses
294,385
376,253
313,373
(Loss) income from operations
(977
)
2,921
(3,433
)
Other expenses (income):
Interest expense
543
462
608
Interest income
(681
)
(173
)
(535
)
Other expense (income) , net
60
(1,057
)
408
(Loss) income before income taxes
(899
)
3,689
(3,914
)
Income tax (benefit) expense
(409
)
997
(161
)
Net (loss) income attributable to common
stockholders
$
(490
)
$
2,692
$
(3,753
)
Net (loss) income per share attributable
to common stockholders - Basic
$
(0.02
)
$
0.08
$
(0.12
)
Net (loss) income per share attributable
to common stockholders - Diluted
$
(0.02
)
$
0.08
$
(0.12
)
Weighted average common shares
outstanding:
Basic
32,282
34,216
32,338
Diluted
32,282
34,597
32,338
Cross Country Healthcare,
Inc.
Reconciliation of Non-GAAP
Financial Measures
(Unaudited, amounts in
thousands, except per share data)
Three Months Ended
March 31,
March 31,
December 31,
2025
2024
2024
Adjusted EBITDA:a
Net (loss) income attributable to common
stockholders
$
(490
)
$
2,692
$
(3,753
)
Interest expense
543
462
608
Income tax (benefit) expense
(409
)
997
(161
)
Depreciation and amortization
4,772
4,642
4,341
Acquisition and integration-related
costsb
2,041
—
4,216
Restructuring costsc
301
938
281
Legal, bankruptcy, and other losses
(gains)d
—
3,650
(928
)
Impairment chargese
—
604
2,170
Loss on disposal of fixed assets
—
—
86
Interest incomef
(681
)
(173
)
(535
)
Other expense (income), net
60
(1,057
)
322
Equity compensation
1,318
1,198
1,698
System conversion costsg
1,164
1,329
926
Adjusted EBITDAa
$
8,619
$
15,282
$
9,271
Adjusted EBITDA margina
2.9
%
4.0
%
3.0
%
Adjusted EPS:h
Numerator:
Net (loss) income attributable to common
stockholders
$
(490
)
$
2,692
$
(3,753
)
Non-GAAP adjustments - pretax:
Acquisition and integration-related
costsb
2,041
—
4,216
Restructuring costsc
301
938
281
Legal, bankruptcy, and other losses
(gains)d
—
3,650
(928
)
Impairment chargese
—
604
2,170
Other (income) expense, net
—
(1,115
)
311
System conversion costsg
1,164
1,329
926
Tax impact of non-GAAP adjustments
(919
)
(1,405
)
(1,843
)
Adjusted net income attributable to common
stockholders - non-GAAP
$
2,097
$
6,693
$
1,380
Denominator:
Weighted average common shares - basic,
GAAP
32,282
34,216
32,338
Dilutive impact of share-based
payments
281
381
68
Adjusted weighted average common shares -
diluted, non-GAAP
32,563
34,597
32,406
Reconciliation:
Diluted EPS, GAAP
$
(0.02
)
$
0.08
$
(0.12
)
Non-GAAP adjustments - pretax:
Acquisition and integration-related
costsb
0.06
—
0.13
Restructuring costsc
0.01
0.02
0.01
Legal, bankruptcy, and other losses
(gains)d
—
0.10
(0.03
)
Impairment chargese
—
0.02
0.07
Other (income) expense, net
—
(0.03
)
0.01
System conversion costsg
0.04
0.04
0.03
Tax impact of non-GAAP adjustments
(0.03
)
(0.04
)
(0.06
)
Adjusted EPS, non-GAAPh
$
0.06
$
0.19
$
0.04
Cross Country Healthcare,
Inc.
Consolidated Balance
Sheets
(Unaudited, amounts in
thousands)
March 31,
December 31,
2025
2024
Assets
Current assets:
Cash and cash equivalents
$
80,697
$
81,633
Accounts receivable, net
219,789
223,238
Income taxes receivable
5,893
10,389
Prepaid expenses
8,295
7,848
Insurance recovery receivable
9,343
9,255
Other current assets
1,182
2,637
Total current assets
325,199
335,000
Property and equipment, net
28,117
28,850
Operating lease right-of-use assets
2,219
2,468
Goodwill
135,060
135,060
Other intangible assets, net
39,965
42,186
Deferred tax assets
8,804
8,104
Insurance recovery receivable
20,193
20,928
Cloud computing
11,358
10,846
Other assets
5,320
5,809
Total assets
$
576,235
$
589,251
Liabilities and Stockholders’
Equity
Current liabilities:
Accounts payable and accrued expenses
$
56,325
$
64,946
Accrued compensation and benefits
50,056
47,646
Operating lease liabilities
1,687
2,089
Earnout liability
—
4,411
Other current liabilities
980
1,310
Total current liabilities
109,048
120,402
Operating lease liabilities
1,623
1,782
Accrued claims
33,982
34,425
Uncertain tax positions
10,168
10,117
Other liabilities
3,204
3,566
Total liabilities
158,025
170,292
Commitments and contingencies
Stockholders’ equity:
Common stock
3
3
Additional paid-in capital
202,074
202,338
Accumulated other comprehensive loss
(1,436
)
(1,441
)
Retained earnings
217,569
218,059
Total stockholders’ equity
418,210
418,959
Total liabilities and stockholders’
equity
$
576,235
$
589,251
Cross Country Healthcare,
Inc.
Segment Datai
(Unaudited, amounts in
thousands)
Three Months Ended
Year-over-Year
Sequential
March 31,
% of
March 31,
% of
December 31,
% of
% change
% change
2025
Total
2024
Total
2024
Total
Fav (Unfav)
Fav (Unfav)
Revenue from services:
Nurse and Allied Staffing
$
242,291
83
%
$
332,186
88
%
$
256,929
83
%
(27
)%
(6
)%
Physician Staffing
51,117
17
%
46,988
12
%
53,011
17
%
9
%
(4
)%
$
293,408
100
%
$
379,174
100
%
$
309,940
100
%
(23
)%
(5
)%
Contribution income:j
Nurse and Allied Staffing
$
17,244
$
27,183
$
20,347
(37
)%
(15
)%
Physician Staffing
4,029
3,138
3,549
28
%
14
%
21,273
30,321
23,896
(30
)%
(11
)%
Corporate overheadk
15,136
17,566
17,249
14
%
12
%
Depreciation and amortization
4,772
4,642
4,341
(3
)%
(10
)%
Restructuring costsc
301
938
281
68
%
(7
)%
Legal and other losses (gains)l
—
3,650
(928
)
100
%
(100
)%
Impairment chargese
—
604
2,170
100
%
100
%
Acquisition and integration-related
costsb
2,041
—
4,216
(100
)%
52
%
(Loss) income from operations
$
(977
)
$
2,921
$
(3,433
)
(133
)%
72
%
Cross Country Healthcare,
Inc.
Summary Condensed Consolidated
Statements of Cash Flows
(Unaudited, amounts in
thousands)
Three Months Ended
March 31,
March 31,
December 31,
2025
2024
2024
Net cash provided by operating
activities
$
5,681
$
6,011
$
24,234
Net cash used in investing activities
(1,886
)
(2,210
)
(2,531
)
Net cash used in financing activities
(4,725
)
(15,653
)
(4,077
)
Effect of exchange rate changes on
cash
(6
)
—
(14
)
Change in cash and cash equivalents
(936
)
(11,852
)
17,612
Cash and cash equivalents at beginning of
period
81,633
17,094
64,021
Cash and cash equivalents at end of
period
$
80,697
5,242
$
81,633
Cross Country Healthcare,
Inc.
Other Financial Data
(Unaudited)
Three Months Ended
March 31,
March 31,
December 31,
2025
2024
2024
Revenue from services
$
293,408
$
379,174
$
309,940
Less: Direct operating expenses
234,750
301,877
247,948
Gross profit
$
58,658
$
77,297
$
61,992
Consolidated gross profit marginm
20.0
%
20.4
%
20.0
%
Nurse and Allied
Staffing statistical data:
FTEsn
7,411
9,124
7,621
Average Nurse and Allied Staffing revenue
per FTE per dayo
$
360
$
397
$
363
Physician Staffing
statistical data:
Days filledp
22,692
23,785
25,427
Revenue per day filledq
$
2,253
$
1,976
$
2,085
(a)
Adjusted EBITDA, a non-GAAP financial
measure, is defined as net income (loss) attributable to common
stockholders before interest expense, income tax expense (benefit),
depreciation and amortization, acquisition and integration-related
(benefits) costs, restructuring (benefits) costs, legal and other
losses, customer bankruptcy loss, impairment charges, gain or loss
on derivative, loss on early extinguishment of debt, gain or loss
on disposal of fixed assets, gain or loss on lease termination,
gain or loss on sale of business, interest income, other expense
(income), net, equity compensation, and system conversion costs.
Adjusted EBITDA is not and should not be considered a measure of
financial performance under GAAP. Management presents Adjusted
EBITDA because it believes that Adjusted EBITDA is a useful
supplement to net income (loss) attributable to common stockholders
as an indicator of operating performance. Management uses Adjusted
EBITDA for planning purposes and as one performance measure in its
incentive programs for certain members of its management team.
Adjusted EBITDA, as defined, closely matches the operating measure
as defined by the Company’s credit facilities. Adjusted EBITDA
Margin is calculated by dividing Adjusted EBITDA by the Company’s
consolidated revenue.
(b)
Acquisition and integration costs relate
primarily to fees associated with the pending Aya Merger.
(c)
Restructuring costs were primarily
comprised of employee termination costs, lease-related exit costs,
and reorganization costs as part of planned cost savings
initiatives.
(d)
Includes legal costs and other settlement
charges as presented on the consolidated statements of operations
and losses pertaining to matters outside the normal course of
operations. The Company incurred a settlement expense of $1.2
million, and recorded a $1.8 million recovery related to a previous
loss, in the fourth quarter of 2024. During the first quarter of
2024, the Company recorded legal and other losses of $3.7 million
representing an offer to settle a lawsuit, as well as estimated
costs related to an unrecoverable asset.
(e)
Impairment charges for the three months
ended March 31, 2024 and December 31, 2024 were related to
right-of-use assets and related property in connection with vacated
leases in those periods. Impairment charges for the three months
ended December 31, 2024 also included the write-off of goodwill and
intangible assets associated with the impairment of a previous
asset acquisition.
(f)
Interest income for the three months ended
March 31, 2025 and December 31, 2024 related to higher average cash
on hand with higher available interest rates.
(g)
System conversion costs include enterprise
resource planning system costs related to the upgrading and
integrating of our middle and back-office platforms, with certain
development costs capitalized and amortized in accordance with the
Company’s policies.
(h)
Adjusted EPS, a non-GAAP financial
measure, is defined as net income (loss) attributable to common
stockholders per diluted share before the diluted EPS impact of
acquisition and integration-related (benefits) costs, restructuring
(benefits) costs, legal and other losses, customer bankruptcy loss,
impairment charges, gain or loss on derivative, loss on early
extinguishment of debt, gain or loss on sale of business, system
conversion costs, and nonrecurring income tax adjustments. Adjusted
EPS is not and should not be considered a measure of financial
performance under GAAP. Management presents Adjusted EPS because it
believes that Adjusted EPS is a useful supplement to its reported
EPS as an indicator of operating performance. Management believes
Adjusted EPS provides a more useful comparison of the Company’s
underlying business performance from period to period and is more
representative of the future earnings capacity of the Company than
EPS. Quarterly non-GAAP adjustment may vary due to rounding.
(i)
Segment data is provided in accordance
with the Segment Reporting Topic of the Financial Accounting
Standards Board Accounting Standards Codification.
(j)
Contribution income is defined as income
(loss) from operations before depreciation and amortization,
acquisition and integration-related (benefits) costs, restructuring
(benefits) costs, legal and other losses, impairment charges, and
corporate overhead. Contribution income is a financial measure used
by management when assessing segment performance.
(k)
Corporate overhead includes unallocated
executive leadership and other centralized corporate functional
support costs such as finance, IT, legal, human resources, and
marketing, as well as public company expenses and Company-wide
projects (initiatives).
(l)
Legal and other losses (gains) include
legal costs and other settlement charges as presented on the
consolidated statements of operations and losses pertaining to
matters outside the normal course of operations.
(m)
Gross profit is defined as revenue from
services less direct operating expenses. The Company’s gross profit
excludes allocated depreciation and amortization expense. Gross
profit margin is calculated by dividing gross profit by revenue
from services.
(n)
FTEs represent the average number of Nurse
and Allied Staffing contract personnel on a full-time equivalent
basis.
(o)
Average revenue per FTE per day is
calculated by dividing Nurse and Allied Staffing revenue, excluding
permanent placement, per FTE by the number of days worked in the
respective periods.
(p)
Days filled is calculated by dividing the
total hours invoiced during the period, including an estimate for
the impact of accrued revenue, by 8 hours.
(q)
Revenue per day filled is calculated by
dividing revenue as reported by days filled for the period
presented.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250506560790/en/
Cross Country Healthcare, Inc. William J. Burns, Executive Vice
President & Chief Financial Officer 561-237-2555
wburns@crosscountry.com
Cross Country Health (NASDAQ:CCRN)
Historical Stock Chart
From Jun 2025 to Jul 2025
Cross Country Health (NASDAQ:CCRN)
Historical Stock Chart
From Jul 2024 to Jul 2025
